Proxy Group's plan is a guillotine, not a scalpel. This device will remove the current head and sew on a new one that talks out of both sides sort of like a Janus figure.
On one side will be saying "We never said ANYTHING about acquiring IncellDX. And we'd never "screw" the regular shareholders."
And from the other mouth, "We'll buy it for $500 mil, have the benefit of the $50,000 it nets each year and get its tests and best of all BRUCE! Wow! And we'll do some heavy duty RSes and finally wrangle a way to take full control of Leronlimab. And the dumbass shareholders will still have their penny stock and own a CytoDyn that will own nothing of value.
For all we know there's another side to the head spewing other ideas...
Moral: Shouldn't let 13d play with sharp objects or with Leronlimab!
News 
Market Data 
Discover 
